Top-Rated StocksTop-RatedNASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free KRYS Stock Alerts $157.38 -0.30 (-0.19%) (As of 02:47 PM ET) Add Compare Share Share Today's Range$155.95▼$160.4150-Day Range$153.12▼$180.4252-Week Range$86.03▼$189.97Volume86,030 shsAverage Volume360,703 shsMarket Capitalization$4.49 billionP/E Ratio1,967.50Dividend YieldN/APrice Target$171.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Krystal Biotech alerts: Email Address Krystal Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside9.2% Upside$171.00 Price TargetShort InterestBearish8.58% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.36Based on 30 Articles This WeekInsider TradingSelling Shares$6.21 M Sold Last QuarterProj. Earnings Growth117.58%From $1.82 to $3.96 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.07 out of 5 starsMedical Sector167th out of 905 stocksBiological Products, Except Diagnostic Industry16th out of 154 stocks 2.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKrystal Biotech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Krystal Biotech's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.58% of the outstanding shares of Krystal Biotech have been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Krystal Biotech has recently increased by 12.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 2.4 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Krystal Biotech this week, compared to 5 articles on an average week.Search Interest7 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,210,591.00 in company stock.Percentage Held by Insiders14.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow by 117.58% in the coming year, from $1.82 to $3.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 1,957.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.22.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 1,957.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 188.66.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 5.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlace1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.Click here to watch his new video ASAP About Krystal Biotech Stock (NASDAQ:KRYS)Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Read More KRYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRYS Stock News HeadlinesMay 9, 2024 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Forecasted to Post Q2 2024 Earnings of $0.37 Per ShareMay 9, 2024 | americanbankingnews.comQ2 2024 Earnings Forecast for Krystal Biotech, Inc. Issued By William Blair (NASDAQ:KRYS)May 9, 2024 | InvestorPlace (Ad)1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.May 8, 2024 | globenewswire.comKrystal Biotech to Present at BofA Securities 2024 Health Care ConferenceMay 8, 2024 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Rating Reiterated by HC WainwrightMay 7, 2024 | finance.yahoo.comKrystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call TranscriptMay 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on Krystal Biotech: Strong VYJUVEK Sales and Promising Pipeline Despite EPS MissMay 7, 2024 | marketwatch.comKrystal Biotech Shares Drop After 1Q Earnings MissMay 9, 2024 | InvestorPlace (Ad)1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.May 7, 2024 | msn.comKrystal Biotech misses top-line and bottom-line estimates; reaffirms FY24 outlookMay 7, 2024 | finance.yahoo.comKrystal Biotech Inc (KRYS) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ...May 7, 2024 | bizjournals.comKrystal Biotech adds to revenue despite challenges in Q1May 6, 2024 | markets.businessinsider.comKrystal Biotech Announces First Quarter 2024 Financial Results and Provides Business UpdatesMay 6, 2024 | finance.yahoo.comKrystal Biotech Inc (KRYS) Surpasses Revenue Estimates in Q1 2024May 6, 2024 | investorplace.comKRYS Stock Earnings: Krystal Biotech Beats EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comKrystal Biotech Announces First Quarter 2024 Financial Results and Provides Business UpdatesMay 4, 2024 | americanbankingnews.comKrystal Biotech (KRYS) to Release Quarterly Earnings on MondayMay 3, 2024 | msn.comKrystal Biotech Q1 2024 Earnings PreviewMay 2, 2024 | globenewswire.comKrystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingApril 26, 2024 | globenewswire.comKrystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024April 24, 2024 | bizjournals.comBrookings takes closer look at Pitt BioForge, Krystal Biotech success in PittsburghApril 22, 2024 | bizjournals.comKrystal Biotech moves to next step in clinical trialApril 22, 2024 | globenewswire.comKrystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the LungApril 18, 2024 | msn.comCentury Real Estate raises ₹450 crore from Edelweiss to buy land and pay debtsApril 15, 2024 | finance.yahoo.comRecent 3.8% pullback isn't enough to hurt long-term Krystal Biotech (NASDAQ:KRYS) shareholders, they're still up 437% over 5 yearsApril 12, 2024 | msn.comKarnataka 2nd PUC Result 2024 DECLARED: How to check Class 12 result at karresults.nic.in, other official websiteApril 12, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros PharmaceuticalsSee More Headlines Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/09/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees229Year Founded2017Price Target and Rating Average Stock Price Target$171.00 High Stock Price Target$204.00 Low Stock Price Target$118.00 Potential Upside/Downside+8.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio1,971.25 Forward P/E Ratio86.64 P/E GrowthN/ANet Income$10.93 million Net MarginsN/A Pretax Margin25.44% Return on Equity-13.31% Return on Assets-12.61% Debt Debt-to-Equity RatioN/A Current Ratio17.76 Quick Ratio17.55 Sales & Book Value Annual Sales$50.70 million Price / Sales88.67 Cash FlowN/A Price / Cash FlowN/A Book Value$27.60 per share Price / Book5.71Miscellaneous Outstanding Shares28,510,000Free Float24,494,000Market Cap$4.50 billion OptionableOptionable Beta0.91 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Krish S. Krishnan M.B.A. (Age 59)M.S., Founder, Chairman, President & CEO Comp: $1.07MMs. Suma M. Krishnan (Age 59)Founder, COO, President of R&D and Director Comp: $789.92kMs. Kathryn A. Romano (Age 42)Executive VP & Chief Accounting Officer Comp: $528.87kMr. John ThomasGeneral Counsel & Corporate SecretaryMr. John KarakkalVice President of North American Sales & MarketingMs. Christine WilsonHead of U.S. Sales and MarketingMr. Josh SuskinDirector of Human Resources & OperationsDr. Hubert C. Chen M.D. (Age 55)Senior Vice President of Clinical Development Mr. Laurent GouxSenior VP & GM of EuropeMr. Ram KamineniSenior Vice President of CMC & Technical OperationsMore ExecutivesKey CompetitorsCRISPR TherapeuticsNASDAQ:CRSPImmunovantNASDAQ:IMVTHalozyme TherapeuticsNASDAQ:HALOIovance BiotherapeuticsNASDAQ:IOVAImmunityBioNASDAQ:IBRXView All CompetitorsInsiders & InstitutionsLord Abbett & CO. LLCSold 126,226 shares on 5/9/2024Ownership: 1.724%Scout Investments Inc.Bought 50,977 shares on 5/9/2024Ownership: 0.179%State Board of Administration of Florida Retirement SystemBought 1,140 shares on 5/9/2024Ownership: 0.026%Mitsubishi UFJ Asset Management Co. Ltd.Sold 102 shares on 5/9/2024Ownership: 0.008%ProShare Advisors LLCBought 486 shares on 5/8/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions KRYS Stock Analysis - Frequently Asked Questions Should I buy or sell Krystal Biotech stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks. What is Krystal Biotech's stock price target for 2024? 9 brokerages have issued 12-month price targets for Krystal Biotech's stock. Their KRYS share price targets range from $118.00 to $204.00. On average, they predict the company's stock price to reach $171.00 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts. How have KRYS shares performed in 2024? Krystal Biotech's stock was trading at $124.06 at the beginning of 2024. Since then, KRYS stock has increased by 26.2% and is now trading at $156.57. View the best growth stocks for 2024 here. When is Krystal Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our KRYS earnings forecast. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings results on Monday, May, 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.17. The firm earned $45.25 million during the quarter, compared to analyst estimates of $47.37 million. The business's quarterly revenue was up 452400.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.76) earnings per share. What ETFs hold Krystal Biotech's stock? ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Jacob Forward ETF (JFWD), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Disruptive Innovation ETF (INNO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA). When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Jennison Associates LLC (2.35%), Lord Abbett & CO. LLC (1.72%), Allspring Global Investments Holdings LLC (0.56%), Allspring Global Investments Holdings LLC (0.56%), TimesSquare Capital Management LLC (0.34%) and Scout Investments Inc. (0.18%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRYS) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 Media348 million Americans lives to END as we know it?The Oxford ClubUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.